Research Australia's 10 Strategic Imperatives: 2015 2025

Research Australia’s

10 Strategic Imperatives

2015 – 2025

RA 10 Strategic Imperatives PR.indd 1

27/01/2015 12:55 pm

Research Australia’s

10 Strategic Imperatives

2015 – 2025

RA 10 Strategic Imperatives PR.indd 2

27/01/2015 12:55 pm

RESEARCH AUSTRALIA

AN ALLIANCE FOR DISCOVERIES IN HEALTH

Research Australia is the nation’s largest alliance working to make health and medical research a higher national priority.

Health and medical research has made a significant contribution in the last century to improved health outcomes around the world, and it holds the promise for even greater advances in the future. Australia has world leading expertise in health and medical research, and Australian governments, companies and individuals make significant investments in health and medical research.

While we are doing well, we can always do better. Research Australia believes that by focusing on the 10 Strategic Imperatives outlined in this document we can maximise the health, social and economic benefits our investment in health and medical research provides to the Australian community and the world.

The 10 Strategic Imperatives will enable us make better use of the resources to: • Contribute to human knowledge and understanding; • Meet the challenges of an ageing population and rising chronic disease; • Contribute to an efficient and effective health system; • Boost wellbeing and productivity; and • Create new jobs and prosperity.

Elizabeth Foley CEO and Managing Director Research Australia

RA 10 Strategic Imperatives PR.indd 3

Christine Bennett AO Chairman Research Australia

27/01/2015 12:55 pm

RESEARCH AUSTRALIA

AN ALLIANCE FOR DISCOVERIES IN HEALTH

Who is Research Australia?

Research Australia is an alliance of 160 members and supporters advocating for health and medical research in Australia. Independent of government, Research Australia’s activities are funded by its members, donors and supporters from leading research organisations, academic institutions, philanthropy, community special interest groups, peak industry bodies, biotechnology, medical technology and pharmaceutical companies, small businesses and corporate Australia. We have a diverse alliance representing the interests of the broader community.

Our Mission Research Australia’s mission is to make health and medical research a higher priority for the nation.

We have four goals that support this mission: • A society that is well informed and values the benefits of health and medical research • Greater investment in health and medical research from all sources • Ensure Australia captures the benefits of health and medical research • Promote Australia’s global position in health and medical research Our vision for Australian health and medical research (H&MR) is better health for all Australians and a stronger Australian economy.

To realise this we need: • World class research capability and productivity; • A higher quality health system; • Vibrant high-tech, innovative healthcare, pharmaceutical, biotechnology and medical technology industries; and • A highly skilled workforce.

Research Australia, through consultation with its broad membership and the general community, has identified ten strategic imperatives required to manifest this vision by 2025.

Initially developed in 2012, the 10 Strategic Imperatives have been reviewed, updated and re-published in 2015.

RA 10 Strategic Imperatives PR.indd 4

27/01/2015 12:55 pm

Research Australia’s

10 Strategic Imperatives

2015 – 2025

01

A healthy and empowered community

06

World class research needs world class researchers

02

Encourage giving

07

Funding research

03

Research active health services deliver higher quality care

08

Encourage commercial investment in R&D

04

Developing implementation science – turning evidence into action

09

A strategic national approach

05

Collaborating for success

10

Reduce red tape

RA 10 Strategic Imperatives PR.indd 5

27/01/2015 12:55 pm

01

A healthy and empowered community

The aim of health and medical research (H&MR) is a healthier community. A community that is less susceptible to disease and that has effective treatments available to it when necessary. A community that better understands its own health and the science that underpins it. A community whose members take control of their own health and participate in decisions about their healthcare and the research that is undertaken on their behalf.

Research Australia believes that greater community understanding and appreciation of H&MR is key to a healthier and more empowered Australian community.

A community that understands and values H&MR is: • Able to use research findings to improve its own health • Supportive of increasing public funds for health and medical research • More likely to make donations to support research • More likely to encourage young people to pursue research careers • More likely to participate in clinical trials and to share their health records, tissue and blood samples with researchers • More realistic in its expectations of the time it takes between discoveries and other ‘breakthroughs’ and the availability of new treatments.

The preferences and priorities of a well informed community are valuable in shaping the research priorities of governments and the research sector.

No longer only wanting to be involved in clinical trials and fund raising, patients and the broader community are becoming involved in the governance of research organisations, strategic decision making, funding allocation and research design.

Research Australia will: • Monitor community attitudes to H&MR through annual opinion polling • Promote H&MR through traditional and social media • Seek to expand the participation of patient groups in the research endeavour.

Research Australia advocates:

86%

of Australians are very or somewhat interested in H&MR but only 30% think it is well communicated.

59% 63%

of Australians are willing to participate in clinical trials*

of Australians are willing to have their tissue samples collected for medical procedures used for research

86%

of Australians have taken action in the past to improve their lifestyle and 66% want more information about actions they can take to improve their health.

• Responsible and balanced media coverage of H&MR activities and achievements • Creating more programs to develop scientific literacy in the community, including programs in schools • The inclusion of patients and community members in the whole of the research process • Accelerating efforts to build and support National Patient Databases • Development of a national rare diseases policy, including a research strategy.

Research Australia, Australia Speaks! 2014 Opinion Poll, views of 1000 Australians and *Research Australia, What do Australians think about Health & Medical Research? 2013 Opinion Poll- views of 1000 Australians, www.researchaustralia.org

RA 10 Strategic Imperatives PR.indd 6

27/01/2015 12:55 pm

02

Encourage giving

Donations are a vital source of research funding alongside private sector investment and governments, and are tangible evidence of the Australian community’s support for H&MR. Giving supplements rather than replaces government and commercial investment, supporting research that is too new, high risk or contentious, or at too early a stage to attract government or commercial funding. It is also significant in encouraging young scientists to pursue a career in research.

There is plenty of scope to encourage greater giving for H&MR and to promote new ways of giving.

Australians generally think that health and medical research is worthy of their support and that they should give more. But there are many good causes and competition for donations can be fierce.

Social media provides new and efficient opportunities to engage with the broader community and encourage individual support for H&MR, and crowd funding provides a means of translating engagement into financial support .

Corporate and individual donors are increasing looking for ‘impact investing’. Put simply, impact investing generates measurable, beneficial social and environmental impacts alongside financial returns.

They want to know that their money is going to a worthwhile reputable research organisation or project and what it will be used to achieve.

We also continue to assist, educate and inform both grant makers and grant seekers on opportunities for investing and receiving funds respectively. Social impact bonds are one way to increase funding to H&MR by individuals who are prepared to accept a discounted investment return for the opportunity to make a socially beneficial investment.

Research Australia advocates: • Removing and/or avoiding creating regulatory barriers to additional philanthropic investment in research • Partnerships between governments and philanthropists to unleash new capital and energy for social and economic good • Promotion of the opportunities for new and innovative forms of giving, including the use of social media, crowd funding and social impact bonds.

H&MR has plenty of potential for significant and lasting impact. However it is a technical and complex area with long timeframes and often uncertain outcomes.

Research Australia is building capability to enhance the relationship between current and potential impact donors and research organisations.

We continue to educate the Australian public on the benefits of giving to health and medical research.

46% 72% 53%

of Australians donate at least annually to H&MR. of these regular donors donate up to $100 per year, and of them believe they should donate more.

Research Australia, Australia Speaks! 2014 Opinion Poll, views of 1000 Australians, www.researchaustralia.org

RA 10 Strategic Imperatives PR.indd 7

27/01/2015 12:55 pm

03

esearch active health R services deliver higher quality care

The aim of H&MR is to benefit the community and it does this most effectively when researchers work closely with healthcare providers.

Health services are enriched and improved when providers are engaged in health and medical research.

Participation in research by health providers in all disciplines and in all settings: • Enables clinicians to more critically appraise new research outcomes • Lifts the overall standard and quality of care • Promotes the more effective and timely translation of research outcomes into practice.

In turn, the engagement of researchers in healthcare delivery helps direct research to the issues that need to be addressed to improve the quality of healthcare.

It also provides opportunities for patients to provide input into the direction of research and to participate in research through clinical trials.

Research should not be seen as a ‘bolt-on’ but as a vital and integral part of the health system, and one of the valued activities and products of health services.

Research Australia advocates: • The creation of more roles in health services across medical, nursing and allied health professions that have a dedicated time and resource allocation to research (i.e. clinician researcher roles) • Routine inclusion of training in research methods and experimental design in the training of health professionals • Activity based funding include time allocated to health and medical research, or the creation of activity based funding for research activity itself, with funding for research activities undertaken by health care providers to be considered by the Independent Health Pricing Authority, • The National Health Performance Authority include performance measures for research as recognition that research activity is a valued outcome of health services.

• Career structures that support moving between research and health delivery roles, and the provision of support to health care practitioners who are participating in research projects on a short-term temporary basis • Provision of infrastructure within our health system to support research, including better support for investigator led and commercial clinical trials • Programs to fund research involvement by primary care providers.

An Academic Health Science Centre brings together healthcare delivery, training and research in a mutually beneficial consortium.

There are several examples overseas in the USA and Europe and more recently from the UK and Canada. Interest in the concept in Australia, including from the National Health and Medical Research Council (NHMRC) and state governments, reflects a renewed focus on bringing research discoveries to the patient.

RA 10 Strategic Imperatives PR.indd 8

27/01/2015 12:55 pm

04

Developing implementation science – turning evidence into action

If the benefits of H&MR discoveries are to be realised, new practices and behaviours that are supported by research need to be adopted by practitioners and the community.

It can take between 10 and 20 years for proven treatments to be implemented routinely into healthcare.

It can take even longer for healthier behaviours to be widely adopted in the community. Identifying and adopting the most effective implementation strategies to change the practices of health service providers and the broader community can reduce this delay.

• Programs to identify and evaluate innovative approaches to healthcare by individual health providers that can be evaluated for their effectiveness and suitability for wider adoption.

A focus on implementation in the health care sector is required to ensure that evidence supported by research is adopted.

This approach will improve the quality of care, leading to faster and more complete recoveries, shorter stays in hospital, and fewer adverse events and readmissions.

This has benefits not only for individual patients but for the system as a whole, helping to reduce pressure on our health system and constrain costs.

Research Australia advocates:

We also need to focus on the most effective ways of introducing healthier behaviours in the community.

• A health system that is open to innovation and the adoption of new technologies and practices, with the capacity to undertake clinical evaluation of their effectiveness.

• Building capacity and investing in implementation research, including comparative effectiveness research • Investment by the health system in ‘change management’ expertise and practice to incentivise and support professionals to adopt new practices and create behavioural change, • Embedding implementation trials into the roll out of new policies and programs to identify successful implementation strategies.

• Collecting data and creating feedback mechanisms for clinicians on their practice and performance.

• Measurement of success for health and medical research. This includes evaluating the likely impact and outcomes of new or proposed research activities, to ensure all types of research have a long term goal of translation.

• Using actual change in practice and policy as part of the ‘track record’ of research success.

• Increasing the availability of existing and potential data sources for research, such as linkage of the Pharmaceutical Benefits Scheme (PBS), Medicare Benefits Schedule (MBS), public and private hospital data and combining of various state registries.

RA 10 Strategic Imperatives PR.indd 9

Research Australia advocates: • Formal evaluation of all public health initiatives to measure their effectiveness in promoting the desired behaviours and improving health outcomes • Investment in research to understand what works and what doesn’t in influencing community behaviours.

‘In Australia, the debate on improving outcomes has relied too much on arguments about increasing resources and not enough on improving productivity and effectiveness through micro economic reform and translation of innovations from research.’

Australian Government, Report of the Strategic Review of Health and Medical Research, 2013, p.17

27/01/2015 12:55 pm

05

Collaborating for success

Modern H&MR is a complex, sophisticated and global endeavour, and collaboration is an essential element. Collaboration makes researchers more productive and effective, improves research quality and ultimately leads to better health outcomes.

Collaboration needs to be supported and encouraged, and barriers to collaboration need to be reduced.

This requires a research culture, funding models and organisational structures that better facilitate, support and reward collaboration, both nationally and internationally.

Collaboration is needed across historic divides: • Between universities, medical research institutes, hospitals and health services, and industry • Between different researchers and across different fields to include disciplines such as economics, engineering, physics and chemistry • Between the public, private and philanthropic sectors • Between various government agencies and departments at all levels • Across Australian state boundaries and internationally.

Research Australia advocates: • A comprehensive review of the barriers to collaboration at institutional levels and between the public, private and higher education sectors, including an examination of global examples of ‘collaborative best practice’ • Programs that encourage collaboration between academic researchers and industry • The provision of research grants to collaborative partnerships or ventures between research organisations, and between research organisations and industry • Greater recognition of the value of international collaboration and additional support for research which attracts overseas funding • Removing barriers to collaboration that exist in the funding programs and recognition/reward systems of academia

• Academic institutions recognising relevant commercial achievements and supporting academic career pathways in and through the private sector • Investment in new modes of research that merge life, physical and engineering sciences Many of the other Research Australia Strategic Imperatives also develop and support a culture of collaboration.

The Australian Hearing Hub at Macquarie University unites researchers, educators, clinicians and innovators with expertise in audiology, speech pathology, cognitive and language sciences, psychology, nanofabrication and engineering sciences. Partners in the facility include: • Macquarie University • Australian Hearing Services • The National Acoustic Laboratories • Cochlear Limited • Royal Institute for Deaf and Blind Children • The Shepherd Centre • Sydney Cochlear Implant Centre • ARC Centre of Excellence in Cognition and its Disorders • The HEARing CRC. http://hearinghub.edu.au ‘… Australia has a small proportion of its research workforce employed in the business sector compared with many other advanced countries.

Such a distinct result should place more emphasis on a high level of industry-(university) research collaboration… However, Australia’s industry(university) research collaboration on innovation is one of the lowest in the OECD.’ Australian Government, Australian Innovation System Report 2013, p.116

RA 10 Strategic Imperatives PR.indd 10

27/01/2015 12:55 pm

06

World class research needs world class researchers

Knowledge and technology have grown over the past decade, affecting the way researchers work and learn. Trends such as personalised medicine and the growing importance of preventive health have created new disciplines and demand for new types of researchers, changing the way researchers approach their work and interact with each other.

For many researchers employment security is only as long as the duration of their latest grant. Many choose to leave the Australian H&MR sector for better conditions and more certainty in other employment here and overseas.

We also need to build better links between research and other careers; not all research is undertaken by individuals for whom research is a full time, life long career. Australia needs to expand its pool of clinician researchers and encourage academic teacher-researchers.

To ensure we have a diverse and sustainable research workforce we need to be able to attract the next generations into research careers, and better manage career interruption for women researchers in particular.

We need a workplace and career structure better able to cater for researchers moving from academia to industry, from health delivery to research, working overseas and returning, as well as returning from career breaks to have families. We need a cultural shift towards greater career flexibility within the sector to avoid skill shortages, build capability and improve productivity. It is cheaper to retain an experienced researcher than to train a new one.

Research Australia supports greater certainty, security and flexibility in research careers. Better research career structures will improve retention and recruitment and boost research productivity.

Research Australia advocates: • Government grants of longer duration to provide greater employment security and assist the retention of talent in the Australian H&MR sector • Training and development of non-traditional and emerging categories of professionals to undertake H&MR from fields such as biomathematics and health economics • The creation of pathways and opportunities for clinicians to engage in research, including making it financially viable to do so • Improved pathways for re-entry to pure research from industry/ commercialisation activity, and from parental leave. This could include salary top-ups through philanthropic funding to attract expatriates back, and a reduction in the emphasis on the quantity and recency of research publications • Providing opportunities for undergraduate and non-PhD post-graduates to do research • Providing research ‘buy-outs’ to enable General Practitioners and other health professionals to engage in research, including clinical trials • Support transitions from PhD to early career researcher.

The Victorian Government’s VESKI Innovation Fellowships have brought

20 top class researchers back home to Victoria from overseas in the decade to 2014.

Bringing this level of expertise and talent back to Australian research institutions is a great way to boost Australian research and promote international collaboration.

RA 10 Strategic Imperatives PR.indd 11

27/01/2015 12:55 pm

07

Funding research

Public funding is the foundation of health and medical research globally.

Governments fund research by their own agencies, such as the CSIRO; provide funding to universities and medical research institutes and for research in hospitals and the community; and they support business activities to commercialise research discoveries.

If we are to continue to enjoy the social and economic benefits of H&MR we need long term, stable and sustainable public funding mechanisms for health and medical research which adequately cover the direct and indirect costs of research and the provision of infrastructure.

We need to build on the sound base that we currently have to make greater use of our existing research capacity and better prepare for the future.

Research Australia advocates: • Government funding bodies working together across different levels of government and portfolios to ensure that grants meet the full cost of the research project/activity, including overheads that are not currently adequately funded • Establishing a target for government expenditure on H&MR each year linked to health expenditure.

• Making adequate provision for the establishment and ongoing operation of key infrastructure such as the Australian Synchrotron which is vital to the Australian research enterprise.

• Investing in linking existing Commonwealth, State and Territory Government registries, tissue banks and databases to facilitate research, and harmonising application and approval processes.

• Adequately funding the active participation of the health care system in H&MR • Publicly funded programs that support research discoveries to the stage where commercialisation or other translation into practice is feasible.

The Strategic Review of Health and Medical Research identified three types of costs associated with medical research: • Direct costs- salaries, equipment and materials • Indirect costs- facilities maintenance, electricity bills, administration expenses etc.

Capital costs- construction of buildings • and large purchases of shared equipment.

It recommended that indirect costs be funded at of the value of the direct research costs.

60%

Australian Government, Report of the Strategic Review of Health and Medical Research, 2013, Recommendation 10

RA 10 Strategic Imperatives PR.indd 12

27/01/2015 12:55 pm

08

Encourage commercial investment in R&D

There are important sources of potential funding for research other than the taxpayer. Research and Development (R&D) within industry and investment from private equity or through traditional capital markets play a vital role in the maintenance and growth of the H&MR sector in Australia.

Commercial investment in research helps to sustain the virtuous cycle of discoveries leading to improved health outcomes.

The pharmaceutical, medical device and biotechnology sectors in Australia are already significant exporters of manufactured goods. Australia can build on this success to create a strong and vibrant advanced manufacturing sector, providing skilled employment and economic growth. But the sector continues to face challenges including lack of access to risk capital, a small domestic market and high operating costs.

Australian biotech company Sementis Ltd is working with the University of South Australia at the University’s Experimental Therapeutics Laboratory on vaccines for a range of conditions.

The partnership gives Sementis access to scientists with expertise in the field of immunology and molecular virology and Sementis provides the environment and infrastructure required for vaccine product development that meets industrial and regulatory needs. www.sementis.com.au/index.php/company/ scientific-team The Medical Research Commercialisation Fund is an example of a collaboration between Commonwealth and State Governments, superannuation funds and universities, medical research institutes and allied health services to commercialise research discoveries. Established in 2007, it is combining research, funding and business acumen to successfully bring Australian research discoveries to market.

Research Australia advocates: • A ‘whole of governments’ national innovation strategy to coordinate, promote and develop innovation in Australia’s public, not for profit and private sectors • Programs and incentives to promote greater collaboration of the private sector with academic researchers • Programs to promote the secondment and placement of publicly funded researchers in private sector institutions to facilitate the transfer of commercialisation skills • Ensuring intellectual property laws appropriately support and encourage investment in R&D • Continuation and expansion of the Australian Government’s dedicated support for commercialisation, including early, mid and late stage commercialisation activities • Researcher career paths that move between universities, medical research institutes and industry need to be encouraged and rewarded • Greater exposure of students to the opportunities for careers in the pharmaceutical, biotechnology and biomedical device industries.

• Policies and programs to capture the benefits of commercial innovation for Australia, including measures to encourage the commercial exploitation of new intellectual property in Australia (eg. schemes like the UK’s ‘patent box’)

www.mrcf.com.au The UK’s Patent Box applies a lower rate of tax to company profits that are earned from patented inventions where the company created or contributed to the patent. www.hmrc.gov.uk

RA 10 Strategic Imperatives PR.indd 13

27/01/2015 12:55 pm

09

A strategic national approach

H&MR is conducted by our higher education institutions, research institutes, governments and corporations and is funded by governments, philanthropy and the private sector. In addition to providing funding there are many government departments with responsibility for areas such as healthcare, industry support, higher education and taxation which indirectly influence the sector.

The research outputs are utilised by healthcare providers and the biotechnology, pharmaceutical and medical technology industries in Australia and around the world. And increasingly, individuals are using this new knowledge to change their own behaviour in pursuit of greater health and wellbeing.

Such complexity requires a considered, holistic national strategy if we are to make the most of our investments of money, intellect and effort. A strategy that recognises H&MR’s role in the healthcare and innovation systems and the broader economy, and is cognisant of Australia’s role in H&MR globally. A strategy that fosters productive relationships between participants and removes barriers to improved productivity at all stages, including in education and training, the conduct of research, the adoption of evidence based practice and commercialisation and manufacturing.

Better alignment of State, Territory and Commonwealth governments’ agendas for the H&MR sector across all portfolios will improve research productivity and maximise the social and economic benefits.

Research Australia advocates: • The Council of Australian Governments (COAG) lead the development of a coordinated, complementary approach to government support of H&MR, including: –E stablishing research priorities, including funding for research in rare and/or neglected diseases and conditions –F acilitating research translation – I mplementing a coherent workforce strategy –M aking structural changes to better embed research into health services –F acilitating collaboration with MRIs, universities and the private sector as part of a national approach to innovation – Promoting the use of Australian research outputs in domestic manufacturing and exports –C alculating overall spend on research and an agreed measure for return on investment.

RA 10 Strategic Imperatives PR.indd 14

• The allocation of funding for research by all levels of government using both a top down and a bottom up approach, so that taxpayers’ dollars are sensibly directed to the priorities of: – Reducing key health burdens – Disease prevention – Supporting investigator/curiosity driven research – Facilitating innovation and the translation of research into new therapies, diagnostics, devices and clinical health policies and practices.

• A national study to forecast the likely capital investment/infrastructure requirements for the H&MR sector over the next 15 years as the basis for combined State, Territory and Commonwealth governments’ infrastructure planning.

• Funding for infrastructure and the other indirect costs of research to follow direct research funding. Commonwealth, State and Territory funding agencies need to provide this support fairly and equitably irrespective of whether the research is being conducted by universities, MRIs or health services.

• Consideration of the health care system’s research needs and how this is to be funded, including determination of responsibility between Commonwealth, State and Territory governments.

• Identifying and measuring the social and economic outcomes of H&MR. Successful implementation of such a strategy will • Improve health and wellbeing, • Constrain costs increases in the health system, and • Drive economic growth.

In April 2014 COAG’s Standing Committee on Health endorsed a project to identify ways to enhance clinical trial activity in Australia by implementing a national approach to clinical trials.

27/01/2015 12:55 pm

10

Reduce red tape

Like all industries, the H&MR sector is subject to some practices and procedures that: • Are unnecessarily complex or time consuming • Impose unnecessary cost • Do not deliver value • Duplicate other activities.

Differing rules and requirements imposed on similar activities by different Commonwealth, State and Territory governments and other organisations create barriers to effective collaborations and multidisciplinary research.

Research Australia supports action to improve the efficiency of the sector by identifying, reforming and eradicating ‘red tape’- practices and procedures that are inefficient and/or ineffective.

Research Australia advocates: • A renewed focus on outcomes when considering how and where to regulate the research sector • The continued harmonisation of clinical trial governance processes • A reduction in the number of Human Research Ethics Committees, further standardisation of research governance and ethical approval processes and the mutual recognition of approvals provided by other NHMRC approved ethics committees for multi-site clinical trial activities • Streamline and optimise access to Commonwealth, State and Territory government registers and databases • A risk oriented and proportionate approach to the regulation of research activities including occupational health and safety • Streamlined pathways for the interchange of personnel between the clinical and research sectors • Continued reform of grant application and assessment processes, including a review of the efficiency of the application, distribution, monitoring and accountability processes • Longer term grants that more comprehensively cover the research costs, thus reducing the number of applications and the time and effort required to secure supplementary funding

Applications for NHMRC grants consume a significant proportion of researchers’ time and have

< 20% success rate.

The NHMRC is working to make the application process more streamlined, saving applicants’ time.

Clinical trial processes have been the subject of significant efforts over several years to reduce the time and cost associated with ethics and governance approvals. Progress has been made and the reform process continues.

RA 10 Strategic Imperatives PR.indd 15

27/01/2015 12:55 pm

Research Australia Members and Partners Foundation Partner

Platinum Partners

Gold Partners

Silver Partners

RA 10 Strategic Imperatives PR.indd 16

27/01/2015 12:55 pm

Bronze Partners

Bioplatforms Australia

Bioplatforms Australia

THE

Bioplatforms Australia

ING

CRC

RA 10 Strategic Imperatives PR.indd 17

27/01/2015 12:55 pm

Research Australia Members List Business & Philanthropic • Brooker Consulting • Clifford Craig Medical Research Trust • Colonial Foundation • Global Philanthropic • Kennedy Austin Executive Search • Macquarie Group Foundation • Ogilvy PR Health • PwC • Roy Morgan • Stafford Fox Medical Research Foundation • Virginia Rigoni Consulting • Vogel Percy and Co

• Children’s Medical Research Institute

• The Walter & Eliza Hall Institute of Medical Research

• Ear Science Institute Australia

• Victor Chang Cardiac Research Institute

• Garvan Institute of Medical Research • Harry Perkins Institute of Medical Research • Hunter Medical Research Institute • Illawarra Health & Medical Research Institute • Ingham Institute

• Westmead Millennium Institute • Women’s & Children’s Health Research Institute

Health Corporates • Abbvie • Amgen Australia

• Institute of Health & Biomedical Innovation

• ATP Innovations

• Kolling Institute of Medical Research

• Bupa Health Foundation

• Lung Institute of Western Australia

• Bioplatforms Australia

• Cochlear Foundation • Cook Medical

Government Agencies

• Mater Medical Research Institute

• CSL

• Biopharmaceuticals Australia

• Menzies School of Health Research

• Genzyme

• Cancer Institute NSW

• GSK

• CSIRO Materials Science & Engineering

• Murdoch Childrens Research Institute

• Health Consult

• Family Planning NSW

• National Ageing Research Institute

• Intersect Australia

• Queensland Office of Health & Medical Research

• Neuroscience Research Australia

• Knowledge Translation Australia

• Orygen Research Centre

• Novartis Pharmaceuticals Australia

H&MRI

• QIMR Berghofer Institute of Medical Research

• ANZAC Research Institute

• Sax Institute

• Australasian Research Institute

• Schizophrenia Research Institute

• Baker IDI Heart & Diabetes Institute

• South Australian Health & Medical Research Institute

• Bionics Institute of Australia

• St. Vincent’s Institute of Medical Research

• Medicines for Malaria Venture

• The Florey Institute of Neuroscience and Mental Health

• Research!America

• Brain & Mind Research Institute • Burnet Institute • Centenary Institute • Centre for Eye Research Australia

• The George Institute for Global Health

• Children’s Cancer Institute Australia

• The Heart Research Institute

RA 10 Strategic Imperatives PR.indd 18

• Roche Products • The HEARing CRC & HEARworks

International Affiliations • FasterCures

• Research Canada

• Research!Sweden • Society for Brain Mapping & Therapeutics

27/01/2015 12:55 pm

RESEARCH AUSTRALIA

AN ALLIANCE FOR DISCOVERIES IN HEALTH

Health Services • Australian Red Cross Blood Service • I-MED Network • Royal Far West • St John of God Healthcare • St. Vincents Health Australia • The Sydney Children’s Hospitals Network • The Women’s & Children’s Health Network

Professional & Industry Associations

Consumer Health Organisations

• Rare Voices Australia • Teachers Health Foundation

• Alzheimer’s Australia Dementia Research Foundation

• The Kids’ Cancer Project

• Arthritis Australia

• The Repat Foundation

• Arts and Health Australia

• The Spinal Cord Injury Network

• AUSiMED • Australian Cancer Research Foundation • Australian Mitochondrial Disease Foundation • Bedside To Bench

Universities • Australian Catholic University • Australian National University • Curtin University

• beyondblue

• Deakin University

• AAMRI

• Bowel Cancer Australia

• Edith Cowan University

• ARCS Australia

• Cancer Council Queensland

• Flinders University

• Audiology Australia

• Cerebral Palsy Alliance

• Griffith University

• AusBiotech

• Cure Brain Cancer Foundation

• James Cook University

• Australasian Research Management Society

• Cure Cancer Australia Foundation

• Macquarie University

• Cure4CF Foundation

• Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists

• Monash University

• Cystic Fibrosis Australia

• RMIT University

• Australian Biospecimen Network Association

• Emergency Medicine Foundation

• Australian SelfMedication Industry • Australian Society for Medical Research • Biomedical Research Victoria • BioMelbourne Network

• Diabetes Australia Research Trust

• Foundation for Alcohol Research & Education

• The University of Notre Dame Australia

• Juvenile Diabetes Research Foundation

• University of Canberra

• Leukaemia Foundation of Australia

• DrinkWise Australia • Life Sciences Queensland Limited

• Motor Neurone Disease Australia

• Medical Technology Association of Australia

• Multiple Sclerosis Research Australia

• NSW Business Chamber • RACP Foundation • Sydney Business Chamber

RA 10 Strategic Imperatives PR.indd 19

• Swinburne University of Technology

• Heart Foundation

• Macular Disease Foundation Australia

• Medicines Australia

• Southern Cross University

• National Breast Cancer Foundation • National Stroke Foundation • Osteoporosis Australia • Prostate Cancer Foundation of Australia

• University of Melbourne • University of Newcastle • University of Queensland • University of South Australia • University of Sydney • University of Tasmania • University of Technology Sydney • University of Western Australia • University of Wollongong

27/01/2015 12:55 pm

Sydney Office 384 Victoria Street DARLINGHURST NSW 2010 Melbourne Office 250 Victoria Parade EAST MELBOURNE VIC 3002

February 2015

www.researchaustralia.org

RA 10 Strategic Imperatives PR.indd 20

27/01/2015 12:55 pm